Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00551070 · OUTCOME

Number of Courses Received

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · Source last updated 2020-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
courses
Interval / dispersion
Inter-Quartile Range
Time frame
Every cycle

Analysis population: Eligible and Treated Patients. Two patients still on study and have received 68 and 79 cycles of treatment.

Groups in this outcome

AZD6244

AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD624452

Reported measurements

Source class 1
Values in courses · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
AZD62445Not reported214Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2
        upper Limit
        14
        value
        5
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    units
    Participants
dispersion Type
Inter-Quartile Range
groups
  1. description
    AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)
    id
    OG000
    title
    AZD6244
param Type
MEDIAN
population Description
Eligible and Treated Patients. Two patients still on study and have received 68 and 79 cycles of treatment.
reporting Status
POSTED
time Frame
Every cycle
title
Number of Courses Received
type
SECONDARY
unit Of Measure
courses

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice